- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Enanta Pharmaceuticals and KalVista Pharmaceuticals Compared in Financial Review
Analysts weigh in on which small-cap biotech stock is the better investment.
Published on Feb. 9, 2026
Got story updates? Submit your updates here. ›
A financial review comparing Enanta Pharmaceuticals (NASDAQ:ENTA) and KalVista Pharmaceuticals (NASDAQ:KALV), two small-cap biotech companies, to determine which is the superior investment. The analysis covers factors like earnings, valuation, profitability, volatility, analyst ratings, and institutional ownership.
Why it matters
This comparison provides investors with insights to help them make informed decisions about allocating capital between these two small-cap biotech stocks, which operate in the competitive pharmaceutical industry and are developing treatments for various viral infections and liver diseases.
The details
The review finds that KalVista Pharmaceuticals has stronger analyst recommendations and a higher potential upside, while Enanta Pharmaceuticals has better profitability metrics and more institutional ownership. Both companies are developing promising drug candidates, but face risks inherent to small-cap biotech firms.
- The analysis was published on February 9, 2026.
The players
KalVista Pharmaceuticals
A clinical-stage pharmaceutical company developing drug therapies for diseases with unmet needs, including hereditary angioedema.
Enanta Pharmaceuticals
A biotechnology company discovering and developing small molecule drugs for the treatment of viral infections and liver diseases.
The takeaway
This analysis highlights the tradeoffs investors must weigh when considering small-cap biotech stocks like KalVista and Enanta. While KalVista may offer more upside potential, Enanta's stronger profitability and institutional backing could make it the safer long-term bet. Investors should carefully evaluate each company's drug pipeline, financials, and competitive positioning to determine which best fits their risk tolerance and investment objectives.
